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Repression of CD24 surface protein
expression by oncogenic Ras is
relieved by inhibition of Raf but not
MEK or PI3K
Nikitha K. Pallegar, D. Craig Ayre and Sherri L. Christian*
Department of Biochemistry, Memorial University of Newfoundland, St. John’s, NL, Canada
CD24 is a dynamically regulated cell surface protein. High expression of CD24 leads
to progression of lung, prostrate, colon, and pancreatic cancers, among others. In
contrast, low expression of CD24 leads to cell proliferation and metastasis of breast
cancer stem cells (BCSCs). Activating mutations in Ras are found in 30% of all
human cancers. Oncogenic Ras constitutively stimulates the Raf, PI3K, and Ral GDS
signaling pathways, leading to cellular transformation. Previous studies have shown that
expression of oncogenic Ras in breast cancer cells generates CD24− cells from CD24+
cells. However, the molecular mechanisms involved in the generation of CD24− cells
were not determined. Here, we demonstrate that oncogenic Ras (RasV12) expression
suppresses CD24 mRNA, protein, and promoter levels when expressed in NIH/3T3
cells. Furthermore, activation of only the Raf pathway was sufficient to downregulate
CD24 mRNA and protein expression to levels similar to those seen in with RasV12
expression. In contrast, activation of the PI3K pathway downregulated mRNA expression
with a partial effect on protein expression whereas activation of the RalGDS pathway
only partially affected protein expression. Surprisingly, inhibition of MEK with U0126 only
partially restoredCD24mRNA expression but not surface protein expression. In contrast,
inhibition of Raf with sorafenib did not restore CD24 mRNA expression but significantly
increased the proportion of RasV12 cells expressing CD24. Therefore, the Raf pathway
is the major repressor of CD24 mRNA and protein expression, with PI3K also able to
substantially inhibit CD24 expression. Moreover, these data indicate that the levels of
CD24 mRNA and surface protein are independently regulated. Although inhibition of Raf
by sorafenib only partially restored CD24 expression, sorafenib should still be considered
as a potential therapeutic strategy to alter CD24 expression in CD24− cells, such as
BCSCs.
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Background
CD24 is a cell surface protein that has various and diverse
roles in cell adhesion and signaling, B lymphocyte and neuronal
development, autoimmune diseases, and cancer (Fang et al.,
2010). In many cancers, such as colorectal, pancreas, and
lung, high expression of CD24 is associated with enhanced
invasiveness and proliferation (Kristiansen et al., 2004). In stark
contrast, forced expression of CD24 in breast cancer cells that
have low CD24 expression (CD24−) leads to decreased cell
proliferation (Ju et al., 2011). Breast cancer cells that have
low expression of CD24 in combination with high expression
of CD44 (CD24−/CD44+) and high aldehyde dehydrogenase
(ALDH) activity are known as breast cancer stem cells (BCSCs)
(Al-Hajj et al., 2003; Douville et al., 2009). BCSCs exhibit
increased invasiveness and proliferation (Sheridan et al., 2006),
and tend to be radiation resistant (Phillips et al., 2006). Tumors
with high percentage of BCSCs generally have a worse prognosis
(Kristiansen et al., 2003) since as few as 1 × 103 BCSCs can
regenerate an entire tumor including both CD24− and CD24+
cells (Yan et al., 2013).
It has been shown that CD24 expression is dynamically
regulated in both CD24+ and CD24− breast cancer cells, with
CD24− cells gaining CD24 expression and vice versa (Meyer
et al., 2009). This dynamic regulation occurs both in vitro
and in vivo and is associated with changes to the invasive
phenotype (Meyer et al., 2009). Moreover, it has been previously
shown that CD24−/CD44+ stem like cells can be generated
from CD24+/CD44− cells after activation of the oncogenic
Ras pathway (Morel et al., 2008). However, the mechanism
underlying this regulation was not established.
CD24 expression can be regulated transcriptionally or post-
transcriptionally. Transcriptional regulation of CD24 varies
widely depending on the cell type. For example, the CD24
promoter contains binding sites for SP-1, which promotes
transcription of CD24 in multiple sclerosis (Wang et al.,
2012) and NFAT5 sites, which promote transcription of CD24
in T-cells in response to hypertonicity (Berga-Bolaños et al.,
2010). In contrast, the estrogen receptor (ER) represses CD24
transcription in ER-positive breast cancer cells (Kaipparettu et al.,
2008). The TWIST transcription factor family can upregulate
or downregulate CD24 expression, with TWIST1 shown to
downregulate CD24 transcription in BCSCs (Vesuna et al.,
2009), and TWIST2 promoting CD24 transcription in human
hepatocarcinoma (Liu et al., 2014). In addition, the CD24
promoter region contains a negative regulatory element located
−983 to−1996 upstream of the transcription start site (TSS) that
can repress CD24 transcription via an unidentified transcription
factor (Pass et al., 1998). Bioinformatic analysis using UCSC
genome browser (Kent et al., 2002) reveals a CpG island between
−828 to +430 bp, relative to the TSS and enhanced methylation
of the Cd24 promoter has been associated with decreased
Abbreviations: BCSCs, Breast cancer stem cells; ER, estrogen receptor;
PI3K, phosphoinositide-3-kinase; ERK, Extracellular signal-regulated kinases;
PLD, phospholipase D; PDK1, phosphoinositide-dependent kinase 1; PDK2,
phosphoinositide-dependent kinase 2; TSS, transcriptional start site. PKC, protein
kinase C; PAK, p21-activated kinase.
expression in glioblastoma cells (Fukushima et al., 2007) and
diseased conjunctiva (Riau et al., 2011). Post-transcriptionally,
the miR34a miRNA has been shown to repress CD24 mRNA
expression via the 3′ untranslated region (Muppala et al., 2013).
Ras is an oncogene with mutations present in approximately
30% of all human cancers (Schubbert et al., 2007) and has
been shown to repress CD24 surface expression (Morel et al.,
2008). Ras activates numerous signaling pathways, including the
Raf, RalGDS, and phosphoinositide-3-kinase (PI3K) pathways to
promote a myriad of cellular functions such as cell proliferation,
cell transformation, and cell survival (McCubrey et al., 2007).
Activation of RalGDS leads to activation of the RalA GTPases
which leads to the subsequent activation of phospholipase D
(PLD) to promote vesicle formation and membrane trafficking
through the golgi (Feig, 2003). Activation of the Raf kinase
leads to the phosphorylation and activation of MEK1/2
(MAP2K; mitogen-activated protein kinase kinase), which
subsequently phosphorylates and activates the extracellular
signal-regulated kinase (ERK1/2). The Raf/MEK/ERK pathway
primarily regulates proliferation and apoptosis (Aksamitiene
et al., 2012). Activation of PI3K leads to phosphorylation of
phosphotidylinositol phospholipids that recruit and promote the
activation of Akt by the PDK1 (phosphoinositide-dependent
kinase 1) and PDK2 (phosphoinositide-dependent kinase 2)
kinases. The PI3K/Akt pathway promotes cell survival, growth
and metabolism in addition to regulating cell migration
(Aksamitiene et al., 2012). The PI3K pathway can also be
activated independently of Ras activation and substantial cross-
talk between the Raf and PI3K pathways has been established
(Aksamitiene et al., 2012).
Despite evidence that overexpression of oncogenic Ras can
repress CD24 surface expression (Morel et al., 2008) the
mechanism for this regulation of CD24 is not known. Here, we
examined the regulation of CD24 mRNA, protein, and promoter
levels in a model of oncogenic Ras activation. We found that
oncogenic Ras can directly repress CD24 mRNA, protein and
promoter activity. We further examined the pathways regulated
by Ras to show that either the PI3K or Raf pathways can repress
CD24 expression. Surprisingly, inhibition of Raf but not MEK or
PI3K significantly increased CD24 surface expression.
Methods
Cells and Treatments
NIH/3T3 cells expressing the empty pBabe vector (control), or
the pBabe vector containing RasV12, RasV12S35, RasV12G37,
or RasV12C40 were gifts from Dr. Kensuke Hirasawa, Memorial
University of Newfoundland (Battcock et al., 2006). All cell
lines were maintained in high-glucose Dulbecco’s Modified Eagle
Medium (DMEM) (Life Technologies Co., Burlington, ON)
supplemented with 10% fetal bovine serum (FBS), 1% anti-
mycotic/antibiotic, 1% sodium pyruvate (complete media) and
maintained at 37◦C in 5% CO2. Control and RasV12 cells
(6 × 104 – 2 × 105 cells/plate) were seeded in 35 and 60mm
plates. At 50–60% confluency, cells were treated with the DMSO
vehicle control, 20µM U0126 (Calbiochem-Millipore, Billerica,
MA), 5, 10, or 20µM sorafenib (Santa Cruz Biotechnology Inc,
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Santa Cruz, CA, USA), or 100µM LY294002 (Calbiochem), as
indicated, in complete media.
RNA Isolation and RT-PCR
RNA was extracted from cells using TRIzol (Life Technologies)
following the manufacturer’s protocol followed by DNase
treatment using the Turbo DNA-free kit (Life Technologies).
RNA (500 ng) was reverse transcribed to cDNA using MMLV-RT
(Life Technologies) with random hexamers, and then amplified
with Taq DNA polymerase (Norgen Biotek, Thorold, ON) using
the primers shown in Table 1. The PCR products were visualized
on 1% agarose gel after staining with ethidium bromide.
Quantitative RT-PCR (RT-qPCR)
RT-qPCR was performed in triplicate using Maxima SYBR Green
qPCRMasterMix (2X) (Thermo Fisher Scientific,Waltham,MA,
USA) for CD24 or RPLP0 using the primers shown in Table 1
with the Eppendorf RealPlex2 Real Time PCR machine. Relative
CD24mRNA levels were normalized using RPLP0 and calculated
using the11Ct equation (Livak and Schmittgen, 2001).
Flow Cytometry
Single cell suspensions (0.2–0.5 × 106 cells for NIH/3T3 derived
cells) were obtained by scraping cells from plates into FACS
buffer [1% heat inactivated FBS in phosphate-buffered saline
(PBS, 1.86mM NaH2PO4.H2O, 8.41mM Na2HPO4, 150mM
NaCl)]. Cells were incubated with 0.5µg anti-CD24 (M1/69), or
Rat IgG2a κ isotype control, conjugated to APC (eBioscience, San
Diego, CA, USA) for 30min on ice, followed by three washes
with FACS buffer then fixed in 4% paraformaldehyde. Data was
collected with a FACS Calibur (BD Biosciences, Mississauga, ON,
Canada) and analyzed using FlowJo software v10.0.5 (Ashland,
OR, USA).
Western Blot Analysis
Cells were washed with PBS and then lysed in RIPA
buffer (50mM Tris-HCl (pH 7.6), 0.02% sodium azide, 0.5%
TABLE 1 | Primers used.
Gene/ Sequence (5′-3′) of forward (F) and
reverse (R) primers
Efficiency Amplicon
Region size
RT-PCR
CD24 F -CTT CTG GCA CTG CTC CTA CC
R -AAC AGC CAA TTC GAG GTG GAC
N/A 300 bp
RPLP0 F -CGG CCC GTC TCT CGC CAG
R -CAG TGA CCT CAC ACG GGG CG
N/A 448 bp
H-Ras F -ATG ACG GAA TAT AAG CTG GTG
R -TCA GGA GAG CAC ACA CTT GCA
N/A 570 bp
RT-qPCR
CD24 F -ACT CAG GCC AGG AAA CGTCTCT
R -AAC AGC CAA TTC GAG GTG GAC
1.07 109 bp
RPLP0 F -TCA CTG TGC CAG CTC AGA AC
R -AAT TTC AAT GGT GCC TCT GG
1.03 101 bp
PROMOTER AMPLIFICATION
−688/-1 F -GTT GGA TGC TCC CGG GTA TGG
R -GGA GCG CGG CCG GCC GGC GG
N/A 688 bp
sodium deoxycholate, 0.1% SDS, 1% NP-40, 150mM NaCl)
containing 1µg/ml aprotinin, 1mM PMSF and 1X HALT
phosphatase inhibitor cocktail (Thermo Fisher Scientific).
Protein concentration was determined by Bicinchoninic acid
(BCA) protein assay (Thermo Fisher Scientific). The samples
were subjected to 10% SDS polyacrylamide gel electrophoresis
and transferred to nitrocellulose membrane, which was blocked
in 5% skimmed milk in Tris-buffered saline (10mM Tris
base, 150mM NaCl, pH7.5) and 0.05% Tween-20 (TBST).
Primary antibodies to detect phosphorylated ERK (Cat #9101),
phosphorylated Akt (Cat #9271), total ERK (Cat #4695), and total
Akt (Cat #9272) were obtained from Cell Signaling Technologies,
Inc (Danvers, MA, USA). Secondary antibodies were obtained
from Santa Cruz Biotechnology Inc. Immobilon Western
Chemiluminescent HRP substrate was used for detection (EMD
Millipore, Darmstadt, Germany) followed by imaging with the
ImageQuant LAS 4000 (GE Healthcare, Morgan Boulevard, Baie
d’Urfe Quebec, Canada).
CD24 Promoter Analysis
Genomic DNA was isolated from a male C57BL/6N mouse liver
using the Genomic DNA isolation kit (QIAGEN, Germantown,
MD, USA). The CD24 promoter region from −688 to −1
from the TSS was amplified from genomic DNA with the GC-
Rich PCR system (Roche, Basil, Switzerland) using the primers
indicated in Table 1. The promoter was cloned into the HindIII
and BglII sites of the pGL4.17 vector (Promega, Madison, USA).
The deletion constructs−469 to−1,−357 to−1, and−168 to−1
were generated using the Erase-a-base kit (Promega) according
to the manufacturer’s instructions. All sequences were verified by
sequencing at The Centre for Applied Genomics (Toronto, ON,
Canada).
Control or RasV12 cells (3 × 104 cells/well in 24-well-
plates) were transfected with 1µg of the pGL4.17 vector with or
without theCD24 promoter regions and 6.66 ng pRL-SV40 vector
(Promega) using 2.5µl Superfect transfection reagent (Qiagen),
following the manufacturer’s instructions. After 24 h, cells were
lysed with 1X Passive Lysis Buffer and Firefly and Renilla
Luciferase activity were measured using the Dual-Luciferase
Reporter Assay kit (Promega).
Results
RasV12 Downregulates CD24 mRNA and Surface
Protein Expression
Previous studies have shown that activation of oncogenic Ras
leads to generation of CD24−/CD44+ stem-like cells from
CD24+/CD44low cells (Morel et al., 2008). To analyze the
regulation of CD24 expression by oncogenic Ras we used a
model system in which constitutively active H-Ras, containing
a G12 to V12 mutation (RasV12), was stably expressed in
the mouse embryonic fibroblast NIH/3T3 cell line (Christian
et al., 2009). The level of CD24 mRNA expression in NIH/3T3
cells stably transfected with empty vector (control cells) or
containing the constitutively active Ras gene was analyzed by
RT-PCR and RT-qPCR (Figures 1A,B). We observed a clear
suppression of CD24 mRNA expression (Figure 1A) that was
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FIGURE 1 | Oncogenic Ras downregulates CD24 expression in NIH/3T3
cells. CD24 mRNA expression in vector control (Control) and RasV12 cells
was determined by (A) RT-PCR and (B) RT-qPCR. RPLP0 was used as the
loading and normalization control. CD24 mRNA levels shown as mean ±
s.e.m. (C) Surface CD24 protein was determined by flow cytometry in Control
and RasV12 cells. One representative histogram of isotype (Iso) and
CD24-stained cells is shown. (D) Quantification of CD24 surface protein
expression as mean ± s.e.m percentage of CD24+ cells. Significance was
determined by Student’s t-test, n = 3, **P < 0.01; ***P < 0.001.
over 1000-fold lower in RasV12 cells compared to control cells
(Figure 1B).
Similarly, analysis of CD24 surface protein by flow cytometry
showed a statistically significant reduction in the percentage of
CD24+ cells in RasV12 population compared to control cells
(Figures 1C,D). Therefore, we can conclude that the reduction
of expression is due to the majority of RasV12 cells losing CD24
expression entirely. Together these data show that constitutively
active Ras significantly downregulates CD24 at both the mRNA
and surface protein expression levels. Residual levels of CD24
are due to a small portion of the population retaining surface
expression.
Ras-mediated Repression of CD24 at the Level of
the Promoter
We next analyzed the activity of the CD24 promoter region
comprising the 688 nucleotides upstream of the TSS (p688)
(Pass et al., 1998). We found that this region is active in
both RasV12 and control cells compared to the promoterless
control (Figure 2A). However, the activity was reduced in
RasV12 cells compared to control cells. To determine if this
difference was statistically significant, we analyzed the relative
activity in RasV12 vs. control cells in comparison to the
promoterless vector, which represents basal activity levels in the
two cell types (Figure 2B). We found that there was a significant
repression of the promoter activity in the RasV12 cells. To
further narrow down the responsive region, we analyzed a series
of CD24 promoter deletion mutants (Figures 2A,B). We found
the relative promoter activity in RasV12 compared to control
cells increased in each deletion mutant compared to the full
promoter. This increase approached statistical significance with
the p469 promoter region (−469 to−1) and reached significance
with the p357 promoter region (−357 to −1). The relative
activity was further increased when the promoter included only
the region from −168 to −1 from the TSS (p168). Therefore,
both the 112 bp region from −469 to −357 and the 189 bp
region from −357 to −168 contain repressive elements that
are regulated by RasV12. However, the sequence within −357
to −168 promoter region appears to contribute more to the
suppression of CD24 than the sequence within the−469 to−357
region.
Activation of Either the Raf or the PI3K Pathway
is Sufficient to Downregulate CD24 Expression
Since we observed that CD24 mRNA and protein expression
are downregulated by Ras, we next asked which pathways
downstream of Ras are sufficient to suppress CD24 expression.
Ras can activate three major pathways, the Raf, RalGDS, and
PI3K pathways, all of which contribute to the fully transformed
phenotype of cancer cells (Hamad et al., 2002). We made use of
NIH/3T3 cells expressing the Ras effector mutants RasV12G37,
RasV12S35, and RasV12C40 (White et al., 1995; Khosravi-Far
et al., 1996; Webb et al., 1998), in which only one pathway is
activated. Specifically, RasV12G37 activates only RalGDS but not
PI3K or Raf. In a similar manner, RasV12S35 selectively activates
the Raf pathway, and RasV12C40 selectively activates the PI3K
pathway.
We observed a downregulation in CD24 mRNA expression
in RasV12S35 and RasV12C40 effector mutants compared to
control cells by RT-PCR (Figure 3A). In contrast, the RasV12G37
cells had similar level of CD24 mRNA expression as the control
cells (Figure 3A). Quantitative analysis of CD24 mRNA by RT-
qPCR revealed the change in CD24 mRNA expression levels in
RasV12S35 and RasV12C40 cells to be statistically significant
when compared to control cells and RasV12G37 but not different
from RasV12 cells (Figure 3B).
We then determined if CD24 surface protein expression was
also affected in Ras effector mutant cells (Figure 3C). We found
that there was a significant and substantial reduction in the
percentage of cells expressing CD24 surface protein in RasV12
and RasV12S35 cells (Figure 3D). RasV12G37 and RasV12C40
expression had an intermediate effect on reducing the percentage
of cells expressing CD24, compared to control cells. Therefore,
activation of the Raf kinase pathway, the PI3K pathway, or the
RalGDS pathway downstream of Ras are sufficient to decrease
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FIGURE 2 | RasV12 represses CD24 promoter activity. (A) Relative
promoter activity in vector control and RasV12 is shown compared to
promoterless vector (pGL4.17). Schematic diagram of promoter deletion
constructs are shown on the left. Promoter length is indicated by the position
upstream of the TSS. (B) Relative promoter activity in RasV12/Control cells for
each reporter construct. Significant differences were determined by One-Way
ANOVA with Tukey Honest Significant Difference post-hoc analysis,
n = 3,−P < 0.1; *P < 0.05; ***P < 0.001, all data are shown asmean± s.e.m.
the CD24+ population. However, activation of the Raf pathway
was sufficient to decrease the CD24+ population to the same
low level as RasV12 suggesting that the Raf pathway is the
major regulator of CD24 expression in these cells. Moreover,
either Raf or PI3K could decrease both CD24 mRNA and
surface expression while RalGDS only partially affected surface
expression.
Inhibition of MEK or PI3K does not Fully Restore
CD24 mRNA Expression
Since we observed that both CD24 mRNA and protein is
significantly and substantially downregulated by the Raf and
PI3K pathways we next determined if inhibition of either or
both of these pathways could restore CD24 expression in RasV12
cells at the mRNA level. The major downstream effectors of
Raf are the MEK1/2 kinases (Gollob et al., 2006), which can be
inhibited specifically with the chemical inhibitor U0126 (Davies
et al., 2000). PI3K can be directly inhibited using LY294002
(Davies et al., 2000; Xue et al., 2007). We evaluated the inhibition
of Raf/MEK/ERK and PI3K/Akt pathways using western blot
analysis of phosphorylated ERK (P-ERK) and phosphorylated
Akt (P-Akt), respectively (Figure 4A). We found that RasV12
cells treated with U0126 had reduced phosphorylation of ERK
with no effect on Akt phosphorylation. Similarly, RasV12
cells treated with LY294002 had reduced phosphorylation
of Akt with no effect on ERK phosphorylation. Treatment
with both U0126 and LY294002 inhibited phosphorylation of
both ERK and Akt. We found that treatment of RasV12
cells with U0126 had a significant 13-fold increase in CD24
mRNA expression (Figures 4B,C). Surprisingly, treatment with
LY294002 alone or in combination with U0126 suppressed CD24
mRNA expression to below the levels seen in RasV12 cells
(Figures 4B,C).
Since U0126 increased CD24 mRNA levels, we next
determined the effect of U0126 on CD24 surface protein
in control cells and RasV12 cells. Unexpectedly, we found
that U0126 increased the percentage of CD24+ cells in the
control cell population (Figures 4D,E). In contrast, there was a
modest but not statistically significant increase in the percentage
of CD24+ RasV12 cells treated with U0126 (Figures 4D,E).
Therefore, even though activation of the Raf pathway is
sufficient to decrease CD24 mRNA and protein, inhibition
of oncogenic Raf/MEK signaling does not restore CD24
expression to the level of control cells at the mRNA or protein
level.
Inhibition of Raf Partially Restores CD24 Cell
Surface Protein Expression in Cells Expressing
Oncogenic Ras but not Control Cells
Since we observed that inhibition of MEK partially restored
CD24 mRNA with no significant effect on protein levels we
next determined if inhibition of Raf directly could restore
CD24 expression levels. Raf is the major downstream target
of Ras and can be directly inhibited by sorafenib, which
does not inhibit MEK or ERK (Wilhelm et al., 2004). We
evaluated the inhibition of Raf/MEK/ERK pathway by sorafenib
at different concentrations using western blot analysis of
phosphorylated ERK (P-ERK) and phosphorylated Akt (P-
Akt) as measures of efficacy and specificity (Figure 5A). We
found that sorafenib reduced ERK phosphorylation in RasV12
cells at all concentrations examined. We also found that both
phosphorylated and total Akt was reduced with 10 and 20µM
sorafenib. Sorafenib is known to inhibit additional kinases such
as EGFR, PDGFR, c-Kit and FLT-3 (Wilhelm et al., 2004; Adnane
et al., 2006), therefore it is not surprising to observe inhibition of
additional pathways with this inhibitor. However, we found that
treatment of RasV12 cells with sorafenib had no effect on CD24
mRNA expression (Figures 5B,C).
We next determined the effect of Raf inhibition by sorafenib
on CD24 surface protein in control cells and RasV12 cells. We
found that treatment with 20µM but not 5 or 10µM sorafenib
significantly increased the percentage of CD24+ cells within
the RasV12 cell population (Figures 5D,E). In contrast to MEK
inhibition, there was no change in the percentage of CD24+ cells
in the control cells after treatment with sorafenib (Figures 5D,E).
Therefore, inhibition of Raf significantly increases the proportion
of CD24+ cells in the absence of changes at mRNA level, but only
in cells expressing oncogenic Ras.
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FIGURE 3 | The Raf and PI3K pathways downregulate CD24 mRNA
expression while the Raf pathway is majorly responsible for
downregulation of CD24 surface protein expression. (A) CD24 mRNA
expression in Control, RasV12, RasV12G37, RasV12S35, and RasV12C40
cells was determined by RT-PCR. H-Ras mRNA expression was used to verify
expression of ectopic Ras. RPLP0 was used as the loading control. (B)
RT-qPCR was used to quantify CD24 mRNA expression with RPLP0 used as
the normalization control. (C) Surface CD24 protein was determined by flow
cytometry. One representative histogram of isotype (Iso) and CD24-stained
cells is shown. (D) Quantification of CD24 surface protein expression as
mean ± s.e.m percentage of CD24+ cells. Significance was determined by
One-Way ANOVA with Tukey Honest Significant Difference analysis, n = 4,
different lower case letters indicating different groups at P < 0.01.
Inhibition of PI3K does not Synergize with Raf
Inhibition to Affect CD24 mRNA or Surface
Protein Expression
We next determined if inhibition of both PI3K and Raf
together could further restore CD24 expression in RasV12
cells at the mRNA and surface protein levels. We evaluated
the inhibition of PI3K/Akt and Raf/MEK/ERK pathways
using western blot analysis of phosphorylated ERK (P-ERK)
and phosphorylated Akt (P-Akt), respectively, as previously
FIGURE 4 | Inhibition of the Raf/MEK/ERK pathway is sufficient to
partially restore CD24 mRNA but not protein expression in RasV12
cells. (A–C) RasV12 cells were treated for 16 h with DMSO (D), or U0126 (U)
and/or LY294002 (LY). (A) Western blot analysis was performed to detect
phosphorylated ERK (P-ERK), and phosphorylated Akt (P-Akt). Total ERK and
total Akt were used as loading controls. Molecular mass standards are shown
in the right of each image. One representative experiment from three replicates
is shown. CD24 mRNA expression in Control and RasV12 cells was
determined by (B) RT-PCR and (C) RT-qPCR. RPLP0 was used as the loading
and normalization control. Significance was determined by One-Way ANOVA
with Tukey Honest Significant Difference post-hoc analysis, *P < 0.05. (D)
Surface CD24 protein was determined by flow cytometry with Control or
RasV12 cells treated for 24 h as above. One representative histogram of
isotype (Iso) and CD24-stained cells is shown. (E) Quantification of CD24
surface protein expression as mean ± s.e.m percentage of CD24+ cells.
Significance was determined by student’s t-test, n = 4, −P < 0.1; **P < 0.01.
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FIGURE 5 | Inhibition of Raf is sufficient to increase CD24 cell surface
protein but not mRNA expression in RasV12 cells. (A–C) Rasv12 cells
were treated for 16 h with DMSO (D) or 5, 10, and 20µM sorafenib (S). (A)
Western blot analysis was performed as in Figure 4. One representative
experiment from three replicates is shown. CD24mRNA expression in Control
and RasV12 was determined by (B) RT-PCR and (C) RT-qPCR as in Figure 4.
Significance was determined by One-Way ANOVA with Tukey Honest
Significant Difference post-hoc analysis, n = 3. (D) Surface CD24 protein was
determined by flow cytometry with Control and RasV12 treated for 24 h as
above. One representative histogram of isotype (Iso) and CD24-stained cells
is shown. (E) Quantification of CD24 surface protein expression as mean ±
s.e.m percentage of CD24+ cells. Significance was determined by One-Way
ANOVA with Tukey Honest Significant Difference analysis, n = 3, different
lower case letters indicate different groups at P < 0.001.
discussed (Figure 6A). Similar to our previous observations,
we found that treatment of RasV12 with LY294002 reduced
phosphorylation of Akt with no effect on phosphorylation
of ERK. Treatment with both LY294002 and sorafenib
inhibited phosphorylation of both ERK and Akt, as
expected. We found that treatment with both LY294002
and sorafenib did not increase CD24 mRNA expression
(Figures 6B,C).
We found that treatment of RasV12 cells with LY294002 alone
did not affect the percentage of CD24+ cells in either control
or RasV12 cells (Figures 6D,E). Moreover, addition of LY294002
did not affect the sorafenib-induced increase in the percentage of
CD24+ cells (Figure 6E). Together, these data indicate that even
though activation of either the PI3K or Raf pathway is sufficient
to decrease CD24 mRNA and protein expression, inhibition of
both PI3K and Raf together is not sufficient to restore CD24
surface protein or mRNA expression.
Discussion
Here, we have demonstrated that expression of oncogenic Ras
is sufficient to directly downregulate expression of CD24 at the
mRNA and protein levels as well as repress promoter activity.
Moreover, activation of either the Raf or PI3K pathway is
sufficient to downregulate CD24 expression at both the mRNA
and protein levels (Figure 7). Surprisingly, inhibition of the Raf
Frontiers in Cell and Developmental Biology | www.frontiersin.org 7 August 2015 | Volume 3 | Article 47
Pallegar et al. Repression of CD24 by Ras
FIGURE 6 | Inhibition of PI3K did not alter the Raf-mediated inhibition
of CD24 expression. (A–C) Rasv12 cells were treated for 16 h with DMSO
(D), 100µM LY294002 (LY) and/or 10 or 20µM sorafenib (S/Sor) with LY.
(A)Western blot analysis was performed as in Figure 4. One representative
experiment from three replicates is shown. CD24mRNA expression in Control
and RasV12 was determined by (B) RT-PCR and (C) RT-qPCR as in Figure 4.
Significance was determined by One-Way ANOVA with Tukey Honest
Significant Difference post-hoc analysis, n = 3, a,bP < 0.01. (D) Surface CD24
protein was determined by flow cytometry with Control and RasV12 for 24 h
as above. One representative histogram of isotype (Iso) and CD24-stained
cells is shown. (E) Quantification of CD24 surface protein expression as
mean ± s.e.m percentage of CD24+ cells. Significance was determined by
One-Way ANOVA with Tukey Honest Significant Difference analysis, n = 3,
different lower case letters indicating different groups at P < 0.001.
pathway, at the level of MEK or Raf, or the PI3K pathway, at
the level of PI3K, either separately or together, was not sufficient
to fully restore CD24 expression in RasV12 cells. However,
inhibition of Raf directly was able to partially restore CD24
surface protein expression without affecting mRNA levels.
Our experimental analysis of the CD24 promoter region
revealed that repression of CD24 promoter activity by oncogenic
Ras was primarily mediated by the 189 bp region between −168
and −357. In addition, a 112 bp region between −357 and −469
also appears to contribute to this repression. We did not observe
any regulation of the previously identified negative regulatory
region (−983 to −1996) (Pass et al., 1998) by oncogenic
Ras (data not shown). Therefore, we have identified a novel
negative regulatory region between −168 and −357 that may
act independently or in cooperation with additional elements
between −357 and −469 to regulate CD24 transcription in
response to oncogenic Ras.
Computational analysis of the 112 bp region revealed more
than 300 potential transcription factor binding sites including
five sites that can bind TWIST transcription factors. However,
deletion of these sites did not affect the repression of CD24
promoter by Ras (data not shown). While regulation of the
CD24 promoter by methylation has been reported in diseased
conjunctiva (Riau et al., 2011) and glioblastoma cell lines
(Fukushima et al., 2007), there was no evidence of promoter
methylation of CD24 in breast cancer cell lines or in patient
tumors (Kagara et al., 2012). Therefore, further work is necessary
to identify the precise regulatory mechanism used by Ras to
repress CD24 transcription.
To narrow down which of the Ras-activated pathways
represses CD24 expression we made use of the Ras effector
mutants, which activate select downstream pathways (White
et al., 1995; Khosravi-Far et al., 1996; Webb et al., 1998).
We found that RasV12S35 cells, in which the Raf pathway
is constitutively active, and RasV12C40 cells, in which the
PI3K pathway is constitutively active, had reduced CD24
mRNA expression compared to control cells. In contrast, the
RasV12G37 cells retained statistically similar mRNA levels to
control cells. With respect to surface protein levels, we found
that CD24 expression was downregulated by all the Ras effector
mutants, including RasV12G37, when compared to control
cells. However, the surface expression of CD24 was statistically
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higher in RasV12G37 and RasV12C40 compared to RasV12 cells.
Strikingly, the surface expression of CD24 in RasV12S35 cells
was downregulated to a statistically similar level as RasV12.
Therefore, together these data suggest that activation of either the
PI3K or the Raf pathway is sufficient to decrease CD24 mRNA
expression but the Raf pathway is the major repressor of CD24
expression at both the mRNA and protein levels.
Unexpectedly, when we performed the complementary loss-
of-function experiments using either the MEK inhibitor U0126
or the Raf inhibitor sorafenib in the presence or absence of
the PI3K inhibitor LY294002, we were unable to restore CD24
mRNA expression to the level of the control cells. Treatment with
U0126 caused a 13-fold increase, which is still 100-fold lower
than the mRNA levels present in control cells, and therefore
may be responsible for the modest but not statistically significant
increase in CD24 surface expression. In contrast, sorafenib
treatment did not alter CD24 mRNA levels. Inhibition of PI3K
alone did not alter CD24 mRNA levels but in combination with
MEK inhibition prevented the U0126-mediated increase in CD24
mRNA expression. Thus, these data suggest that the inhibition of
the PI3K pathway could potentially activate a repressor or inhibit
an activator of CD24 mRNA expression to block the effects of
U0126 treatment. Consistent with this hypothesis, significant
cross-talk between the PI3K and Raf pathways has been shown,
including the ability of Akt to inhibit Raf. As we did not observe
an increase in ERK phosphorylation, the possible relief of Akt-
mediated inhibition of Raf did not override the U0126-mediated
block in MEK activation. Thus, inhibition of the PI3K pathway
may relieve the Akt-mediated inhibition of Raf and promote
Raf-mediated suppression of CD24 (Figure 7).
Interestingly, sorafenib treatment significantly increased the
proportion of CD24+ RasV12 cells while U0126 treatment
significantly increased CD24+ cells only in the control cell
population. This suggests that regulation at the level of Raf
regulates CD24 expression in oncogenic conditions while
MEK can regulate CD24 expression in response to basal
growth conditions. In both situations ERK phosphorylation
is equally inhibited, therefore the regulation of CD24 surface
expression cannot be downstream of ERK activation. Together,
these data demonstrate that the regulation of CD24 surface
protein expression is regulated in a Raf-dependent, MEK-
independent manner. Furthermore, these data suggest that
additional pathways remain activated in the presence of the
Raf, MEK, or PI3K inhibition that can continue to repress
CD24 expression. For example, as depicted in Figure 7, both
p21 protein (Cdc42/Rac)-activated kinase (PAK) and Protein
Kinase C (PKC) can positively regulate the Raf/MEK/ERK
pathway at multiple levels to bypass Raf or MEK inhibition
(Kaga et al., 1998; Jimenez et al., 2000; Aksamitiene et al.,
2012).
These inhibitor experiments as well as our observation that
there is a reduction in CD24 cell surface protein expression but
not mRNA expression in RasV12G37 cells strongly suggest that
the downregulation of CD24 mRNA and surface expression are
not mediated by the same mechanisms. CD24 has substantial
post-translational modifications, including protein cleavage,
addition of the GPI-anchor, and major O- and N-linked
FIGURE 7 | Schematic representation of the regulation of CD24 by
Ras/Raf and Ras/PI3K pathways. Rectangles represent proteins and ovals
represent lipids and second messengers. Protein activation is indicated by
solid arrows and inhibition indicated by solid lines with blunt ends. Potential
mechanisms for cross-talk are shown in gray. The effect of U0126 and
LY294002 on MEK and PI3K and on CD24 transcription is indicated by
dashed lines and dash dot dash lines, respectively. The effect of sorafenib on
Raf and on CD24 surface protein expression is indicated by dotted lines. The
CD24 promoter is indicated with a solid line flanked by genomic DNA depicted
with a dotted line. The transcription start site is indicated by a bent arrow.
Abbreviations not in the main text: PLC-γ, phospholipase C- γ; PIP3,
phosphotidylinositol-3,4,5-trisphosphate; DAG, diacylglycerol; Cdc42, cell
division cycle 42.
glycosylations that occur prior to surface expression (Fang
et al., 2010). Thus, the Ras/Raf or the Ras/Ral pathways may
also regulate post-translational modification or trafficking. The
interaction of Raf-1 with the actin cytoskeleton has been shown
to be necessary for efficient activation of MEK/ERK (Wang et al.,
2013), but no Raf-mediated MEK-independent regulation of
protein trafficking has been reported. On the other hand, Ral is
well-known to regulate vesicle trafficking (Feig, 2003). While Ral
can be activated in a Ras-independent manner (Linnemann et al.,
2002), it is not known if Ral can be activated in a Raf-dependent
manner. Alternatively, alteration of GPI-anchor biosynthesis
by Ras as, previously identified in Saccharomyces cerevisiae
(Sobering et al., 2004), may be responsible for altering CD24
surface expression. Therefore, future work will be necessary
to unravel the precise mechanism that regulates CD24 surface
protein expression by the Ras/Raf pathway.
As described earlier, high CD24 expression is associated
with promoting proliferation in lung, prostate, and colorectal
cancer (Kristiansen et al., 2004), while low CD24 expression is
associated with proliferation in BCSCs (Sheridan et al., 2006).
This paradoxical relationship does not yet have a mechanistic
explanation but may be related to the cell type of origin.
Our model system clearly recapitulates the BCSC phenotype of
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oncogenic Ras and transformation being associated with low
levels of CD24 (Marcato et al., 2009).
CD24 expression is dynamically regulated throughout the
development of B and T lymphocytes, dendritic cells, neurons,
and adipocytes (Nathan et al., 1986; Smith et al., 2015; Tan
et al., 2015). Moreover, CD24 expression in some normal cell
types is associated with proliferation or differentiation (Li et al.,
2004; Smith et al., 2015), while in others it is associated with
apoptosis (Suzuki et al., 2001). Therefore, transformation of
a particular cell type at a particular cell stage may dictate
if CD24 promotes or inhibits proliferation. Previously, it was
found that overexpression of oncogenic H-Ras as the last step
in the sequential transformation of primary human mammary
epithelial cells or in immortalized MCF10A cells resulted in an
epithelial to mesenchymal transition (EMT) concomitant with
the downregulation of CD24 surface expression (Morel et al.,
2008). Here we have found that expression of oncogenic Ras in
mouse embryonic fibroblasts, which are already mesenchymal,
represses CD24 mRNA and protein expression, and promoter
activity. Therefore, it may be the mesenchymal phenotype that
predisposes a cell to lose CD24 expression in response to Ras
transformation while other cell types will gain or retain CD24
expression dependent on their epithelial vs. mesenchymal status.
Overall, understanding the regulation of CD24 expression
by oncogenic Ras may promote development of therapeutic
strategies to induce BCSCs to gain CD24 expression. This
strategy would decrease the percentage of BCSCs in the
tumor and therefore reduce the ability of the tumor to be
radiation-resistant or initiate secondary tumor formation.
We have demonstrated that CD24 expression is directly
suppressed by oncogenic Ras, however, while inhibition of the
MEK was sufficient to partially restore CD24 expression at
the mRNA level, inhibition of Raf was necessary to increase
CD24+ cells. Thus, these data clearly demonstrate that the
oncogenic Ras-mediated suppression of CD24 expression is
regulated at multiple levels. However, as sorafenib clearly
increases the population of CD24+ cells, this clinically
relevant therapeutic should be considered in situations where
shifting the population of CD24− toward CD24+ would be
beneficial.
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